| 摘要 |
Heterocyclic GPCR agonists Compounds of formula (I) as agonists of GPR119 for use in the treatment of metabolic disorders, including type II diabetes, metabolic syndrome (syndrome X), impaired glucose tolerance, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels or hypertension. Within formula (I) A is a para-substituted phenyl or para-substituted 6-membered heteroaryl ring containing 1-3 nitrogen atoms; R2 is , or an optionally substituted phenyl, pyridyl, N-pyridonyl or N-pyrazolyl; Z is -C(O)OR4, -C(O)R4, -S(O)2R4, -S(O)2N(C1-3alkyl)R4, heteroaryl or -CH2-heteroaryl and when p and q are both 0, Z can also be -CH2-phenyl wherein the phenyl is optionally substituted; X is selected from CR5H, O, NR6 in which R5 and R6 are independently hydrogen or C1-2alkyl; R1, R3, R4 and R11 are each independently substitutents; Y is Y1 or W-Y1 where W is a 5 membered heteroaryl ring containing one or more heteroatoms selected from N, O and S and Y1 is selected from CR7H, O and NR8 wherein R7 and R8 are substituents, provided that when Y is W-Y1, X is O and Y1 is CR7H, when Y1 is NR8, X is CR5H and when X is O or NR6, Y1 is CR7H; R9 and R10 are each independently H, halo, C1-2alkyl, C1-2haloalkyl, C1-3alkoxy or hydroxyl; or R9 and R10 are joined to form an azabicyclo[3.3.1]nonane, a 3-oxa-7-azabicyclo[3.3.1]nonane or an aqzabicyclo[3.2.1]octane; m is 0, 1 or 2, n is 0 or 1; p and q are each 0, 1 or 2 provided that 0â ¤p+qâ ¤2 and r is 1 or 2. Also outlined are compounds where Z is -C(O)R12; where R12 is -NHC(O)R13 or â NHC(NH)R13 and R13 is a substitutent. Compounds having the stereochemistry of formula (Ia) may also demonstrate DPP-IV inhibitory activity.
|
